- ALSO READ
Drugmakers Sanofi and GlaxoSmithKline have agreed to provide 200 million doses of their potential Covid-19 vaccine to the COVAX Facility, a collaboration designed to give countries around the world equal access to coronavirus vaccines.
The Sanofi-GSK vaccine candidate is in early stage trials, with results expected in early December. The drugmakers said Wednesday that they plan to begin phase three trial by the end of the year and request regulatory approval of the vaccine in the first half of 2021.
The facility is part of COVAX, a coalition of governments, health organisations, businesses and charities working to accelerate the development of Covid-19 vaccines.
Thomas Triomphe, head of Sanofi's vaccine unit, said: To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control.
Almost 44 million people have been confirmed to be infected with the virus worldwide and 1.16 million of them have died, according to a tally by Johns Hopkins University.
Experts say the true toll of the pandemic is much greater than that, due to limited testing, missed mild cases and concealment of cases by some governments.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
First Published: Wed, October 28 2020. 14:29 IST